Observational studyJournal of the American Heart Association2022
Serum Neurofilament Light Chain in Patients With Atrial Fibrillation.
Observational study in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Plasma Profiles of Neuroglial Injury Biomarkers after Ischemic Stroke.Translational stroke research · 2025Observational
- Inflammaging and the sex-frailty paradox.Aging clinical and experimental research · 2025Article
- Left Atrial Myocardial Mechanics: Association With Cognitive Dysfunction, Cerebrovascular Disease, and Circulating Biomarkers.Journal of the American Heart Association · 2025Article
- Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation.Journal of the American Heart Association · 2025Article
- Advancing Clinical Use of Neurofilament Light Chain: Translational Insights From Research to Routine Practice.Biomarker insights · 2025Review
- Impact of amyloid and cardiometabolic risk factors on prognostic capacity of plasma neurofilament light chain for neurodegeneration.Alzheimer's research & therapy · 2024Observational
- The association between joint Serum Neurofilament Light Chain and type 2 diabetes with all-cause and cardiovascular mortality in US adults: a longitudinal study of NHANES.BMC endocrine disorders · 2024Article
- Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms.Blood cancer journal · 2024Article
- Neurofilaments as biomarkers in neurological disorders - towards clinical application.Nature reviews. Neurology · 2024Review
- Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies.Neurodegenerative disease management · 2024Review
- Negative association of serum neurofilament light chain with estimated glomerular filtration rate levels and the impact of gender.Frontiers in neurology · 2024Article
- Fluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the Bedside.International journal of molecular sciences · 2023Review
- Neurologic Biomarkers, Neuroimaging, and Cognitive Function in Persistent Atrial Fibrillation: A Cross-Sectional Study.International journal of molecular sciences · 2023Article
- Prediabetes is associated with a higher serum neurofilament light chain level in adolescents.Frontiers in endocrinology · 2023Article
- Cardiovascular rate pressure product is associated with NfL in older adults at risk for AD.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Atrial fibrillation (AF) is associated with stroke and MRI features of cerebral tissue damage but its impact on levels of serum neurofilament light chain (sNFL), an established biochemical marker of neuroaxonal damage, is unknown. Methods and Results In this observational study, sNFL was analyzed in 280 patients with AF and 280 controls without AF matched for age, sex, and diabetes status within the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. None of the patients had a history of previous stroke or transient ischemic attack. Patients with a diagnosis of AF were divided into two groups based on if they were in AF rhythm at the time of blood sampling (AF ECG+, n=74), or not (AF ECG-, n=206). Multiple linear regression analysis was performed to adjust for clinical risk factors. In patients with AF, the levels of sNFL were 15% (AF ECG+) and 10% (AF ECG-) higher than in the control group after adjustment for clinical risk factors,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.